{{Rsnum
|rsid=12828172
|Gene=KSR2
|Chromosome=12
|position=117490377
|Orientation=plus
|GMAF=0.3306
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=KSR2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 25.2 | 60.4 | 14.4
| HCB | 58.1 | 36.8 | 5.1
| JPT | 48.7 | 43.4 | 8.0
| YRI | 62.3 | 31.5 | 6.2
| ASW | 54.4 | 38.6 | 7.0
| CHB | 58.1 | 36.8 | 5.1
| CHD | 56.6 | 36.8 | 6.6
| GIH | 21.8 | 44.6 | 33.7
| LWK | 60.7 | 32.7 | 6.5
| MEX | 33.3 | 43.9 | 22.8
| MKK | 52.9 | 37.3 | 9.8
| TSI | 33.3 | 50.0 | 16.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12828172
|Name_s=
|Gene_s=KSR2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.000004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109340
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12828172
|overall_frequency_n=43
|overall_frequency_d=126
|overall_frequency=0.34127
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=32
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}